Currax’s first acquisition comes fewer than five months after the company’s founding in April of 2019
The acquisition of ONZETRA® Xsail® bolsters Currax’s Branded products portfolio
Currax Pharmaceuticals LLC, a specialty biopharmaceutical company with both Branded and generic business units, announced today a deal whereby Currax obtained patent rights to ONZETRA® Xsail® (sumatriptan nasal powder) in North America from OptiNose AS, a subsidiary of OptiNose, Inc. (Nasdaq: OPTN).
ONZETRA® Xsail® provides a 22mg dose, dry powder formulation of sumatriptan, administered via a breath powered exhalation delivery system and is approved by the U.S. Food and Drug Administration (FDA) for the acute treatment of migraine in adults with or without aura.
Want to publish your own articles on DistilINFO Publications?
Send us an email, we will get in touch with you.
“Despite the recent advances in migraine therapy, many patients still suffer debilitating migraine pain and are dissatisfied with their current treatments,” said Stewart Tepper, MD professor of Neurology, Geisel School of Medicine at Dartmouth. “The Xsail® Breath Powered delivery device allows the medication to be deposited deep into the nose, an area that is rich with blood vessels. By delivering sumatriptan here, ONZETRA® Xsail® provides targeted and efficient delivery with the potential for fast relief.”
“We are pleased to announce our first acquisition so early in the lifecycle of our company,” said George Hampton, chief executive officer at Currax Pharmaceuticals LLC. “This acquisition is in line with both our focus to create greater patient access to life changing medicines and our business growth strategy to acquire underappreciated and clinically differentiated medicines.”
Date: September 30, 2019
Source: Prnews Wire
